Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Lafata, J.E. et al.

Jennifer Elston Lafata, Mirela Cerghet, Elizabeth Dobie, Lonni Schultz, Kaan Tunceli, Jacqueline Reuther, Stanton Elias,

Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis.

OBJECTIVES: To measure disease-modifying agent adherence and persistence among patients with multiple sclerosis (MS). DESIGN: Retrospective cohort study. SETTING: Multispecialty, salaried group practice in southeast Michigan, between June 1, 2004, and June 30, 2006. PATIENTS: 224 insured adult patients with relapsing remitting MS with an outpatient visit. MAIN OUTCOME MEASURES: Medical record-documented receipt of medication recommendation and prescription. Pharmacy claims data-derived measures of dispensing and among patients with two or more dispensings, medication possession ratios (MPRs), and proportion of gap days were estimated. Among those initiating agent use, persistence was estimated. RESULTS: Mean cohort age was 47.6 years, while 77% of participants were women and 39% were black. Of patients, 81.8% had a recommendation for a disease-modifying agent, 75.0% had a prescription, and 66.5% had two or more dispensings. Among those with two or more dispensings, mean MPR between the first and last dispensing date was 83.8% (95% CI 80.8-86.8), while mean MPR for the entire 24-month period was 68.0% (64.4-71.7). MPR for the 24-month period decreased with increasing drug copayments and was lower among black patients, while MPR between the first and last dispensing date increased with increasing age. Among those initiating therapy, 43% were nonpersistent with medications within 14 months. CONCLUSION: Medication adherence and persistence among patients with relapsing remitting MS is far from monolithic. Measuring medication adherence and persistence among defined populations is useful for understanding the relationship between medication use and outcomes in practice and for targeting patients and programs to improve medication adherence.[1]

References

Measuring adherence and persistence to disease-modifying agents among patients with relapsing remitting multiple sclerosis. Lafata, J.E., Cerghet, M., Dobie, E., Schultz, L., Tunceli, K., Reuther, J., Elias, S. J. Am. Pharm. Assoc. (2003) (2008) [Pubmed]

Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.